The Problems We Solve
At Onconox, we focus on some of the most pressing and persistent gaps in modern medicine. Patients living with cancer and neurodegenerative conditions continue to face limited therapeutic options, high treatment burden, and biological barriers that restrict the impact of current therapies. Our mission is to address these challenges through precision-delivered, better-tolerated, and scalable therapeutic innovation.
Our platform is purpose-built to overcome these long-standing limitations and unlock meaningful improvements in survival, quality of life, and patient access.
Unmet Needs in High-Burden Diseases
Cancer and neurodegenerative conditions account for some of the highest morbidity, mortality, and economic burden globally, yet therapeutic innovation has not kept pace with patient need. In oncology, many treatments offer only incremental improvements with substantial toxicity. In CNS disorders, the blood–brain barrier continues to block effective delivery of promising therapies.
Why it matters:
Patients facing these diseases have fewer effective options compared to other therapeutic areas, and many remain underserved by existing systemic treatments.
How we solve it:
We focus on diseases where the combination of high unmet need, biological complexity, and delivery challenges demand new approaches. Our precision delivery strategy enables therapies that are more targeted, more tolerable, and more compatible with the realities of cancer and CNS care.
Systemic Toxicity & Patient Burden
Most cancer and CNS drugs circulate throughout the body, even when only a small anatomical region requires treatment. This results in avoidable toxicity, dose reductions, treatment delays, and long-term side effects that significantly impact quality of life. Frail, elderly, and comorbid patients are often unable to tolerate systemic regimens at all.
How we solve it:
We design therapies that act where the disease is — not where it isn’t. By delivering treatment directly to the lungs, the brain, or the tumor itself, we aim to improve tolerability, reduce systemic exposure, and support better adherence through patient-friendly administration routes.
Inefficient & Risk-Prone Development
Traditional drug development is slow, costly, and characterized by high attrition. It often takes more than a decade for a new therapy to reach patients, and most early-stage programs fail due to safety, efficacy, or translational uncertainty.
How we solve it:
Our BIG Platform uses validated small-molecule foundations, intelligent repurposing, targeted delivery modalities, and AI-supported prioritization to accelerate development and reduce scientific, financial, and operational risk. This model creates faster, more predictable paths to clinical proof and value creation.
Radiotherapy Lacks Safe and Effective Enhancers
Despite being a core part of treatment for more than half of all cancer patients, radiotherapy has seen limited therapeutic innovation. Few agents exist to safely improve tumor responsiveness to radiation, and those that do tend to be systemic and poorly tolerated.
How we solve it:
We are developing targeted, well-tolerated therapies designed to enhance the effect of radiotherapy directly at the site of disease. By improving local synergy without increasing systemic toxicity, our approach seeks to boost tumor control while maintaining patient quality of life.
Tumors and the Brain Are Difficult to Reach with Conventional Therapies
Biological barriers such as the blood–brain barrier, poor lung deposition, and tumor microenvironment complexity limit the effectiveness of systemically delivered drugs. As a result, many promising therapeutics fail to reach their intended target in sufficient concentration.
How we solve it:
Our delivery innovations — inhaled, intranasal, and direct-to-tumor — are engineered to overcome these barriers. We aim to place therapeutics where they are needed most, supporting deeper tissue penetration, improved pharmacokinetics, and more consistent therapeutic effect.
The Industry Lacks Scalable Platform Technologies
Most early-stage biotech’s rely on single-asset strategies that create binary risk, slow progress, and limited resilience. Without shared scientific or operational infrastructure, each program becomes a costly standalone effort.
How we solve it:
The BIG Platform is a modular, multi-asset engine that transforms one validated pharmacological backbone into multiple differentiated therapies. By sharing formulation logic, manufacturing pathways, and translational insights across programs, we reduce duplication, increase efficiency, and build a sustainable innovation model capable of repeated value creation.
Unmet Needs in High-Burden Diseases
Cancer and neurodegenerative conditions account for some of the highest morbidity, mortality, and economic burden globally, yet therapeutic innovation has not kept pace with patient need. In oncology, many treatments offer only incremental improvements with substantial toxicity. In CNS disorders, the blood–brain barrier continues to block effective delivery of promising therapies.
Why it matters:
Patients facing these diseases have fewer effective options compared to other therapeutic areas, and many remain underserved by existing systemic treatments.
How we solve it:
We focus on diseases where the combination of high unmet need, biological complexity, and delivery challenges demand new approaches. Our precision delivery strategy enables therapies that are more targeted, more tolerable, and more compatible with the realities of cancer and CNS care.
Systemic Toxicity & Patient Burden
Most cancer and CNS drugs circulate throughout the body, even when only a small anatomical region requires treatment. This results in avoidable toxicity, dose reductions, treatment delays, and long-term side effects that significantly impact quality of life. Frail, elderly, and comorbid patients are often unable to tolerate systemic regimens at all.
How we solve it:
We design therapies that act where the disease is — not where it isn’t. By delivering treatment directly to the lungs, the brain, or the tumor itself, we aim to improve tolerability, reduce systemic exposure, and support better adherence through patient-friendly administration routes.
Inefficient & Risk-Prone Development
Traditional drug development is slow, costly, and characterized by high attrition. It often takes more than a decade for a new therapy to reach patients, and most early-stage programs fail due to safety, efficacy, or translational uncertainty.
How we solve it:
Our BIG Platform uses validated small-molecule foundations, intelligent repurposing, targeted delivery modalities, and AI-supported prioritization to accelerate development and reduce scientific, financial, and operational risk. This model creates faster, more predictable paths to clinical proof and value creation.
Radiotherapy Lacks Safe and Effective Enhancers
Despite being a core part of treatment for more than half of all cancer patients, radiotherapy has seen limited therapeutic innovation. Few agents exist to safely improve tumor responsiveness to radiation, and those that do tend to be systemic and poorly tolerated.
How we solve it:
We are developing targeted, well-tolerated therapies designed to enhance the effect of radiotherapy directly at the site of disease. By improving local synergy without increasing systemic toxicity, our approach seeks to boost tumor control while maintaining patient quality of life.
Tumors and the Brain Are Difficult to Reach with Conventional Therapies
Biological barriers such as the blood–brain barrier, poor lung deposition, and tumor microenvironment complexity limit the effectiveness of systemically delivered drugs. As a result, many promising therapeutics fail to reach their intended target in sufficient concentration.
How we solve it:
Our delivery innovations — inhaled, intranasal, and direct-to-tumor — are engineered to overcome these barriers. We aim to place therapeutics where they are needed most, supporting deeper tissue penetration, improved pharmacokinetics, and more consistent therapeutic effect.
The Industry Lacks Scalable Platform Technologies
Most early-stage biotech’s rely on single-asset strategies that create binary risk, slow progress, and limited resilience. Without shared scientific or operational infrastructure, each program becomes a costly standalone effort.
How we solve it:
The BIG Platform is a modular, multi-asset engine that transforms one validated pharmacological backbone into multiple differentiated therapies. By sharing formulation logic, manufacturing pathways, and translational insights across programs, we reduce duplication, increase efficiency, and build a sustainable innovation model capable of repeated value creation.
Our Purpose
We exist to redefine what patients should expect from treatment: smarter therapies, fewer side effects, and meaningful improvements in survival and quality of life.
By overcoming toxicity, inefficiency, and delivery barriers, we are building a new class of precision therapeutics designed for real clinical impact.